GlobalData on MSN20h
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical on MSN1d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...
Zacks.com on MSN1d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
3d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback